Ranbaxy has first-to-file status, meaning eligibility for six months of generic sales exclusivity for both AstraZeneca's heartburn drug Nexium & Roche's antiviral drug Valcyte drugs. However, the final approvals for these drugs were delayed because of the compliance issues at Ranbaxy's plants.
first published: Nov 7, 2014 10:14 am
A collection of the most-viewed Moneycontrol videos.
Live: Nifty recovers 100 pts from day's lows in a choppy session; smallcaps shine | Closing Bell
Live: Can Nifty reclaim 26,000 after RS 7.5 lakh crore selloff? | IndiGo in focus | Opening Bell
Live: Sensex, Nifty fall 1% amidst broad-based selloff | Closing Bell
Live: Can Nifty reclaim record levels as investors await FOMC decision this week? | Opening Bell
